All In MedTech

FDA Clearance Tracker · P200015-S068

Edwards SAPIEN 3 Transcatheter Pulmonic Valve Delivery System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 28, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 28, 2026

Approved

Time to decision

180 days

Received Aug 1, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

The decision

FDA number
P200015-S068
Device name
Edwards SAPIEN 3 Transcatheter Pulmonic Valve Delivery System
Applicant location
Irvine, CA
Received
Aug 1, 2025
Decided
Jan 28, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P200015

Device type

Every decision under product code NPV

FDA's approval statement

As written in FDA's record.

Approval for the next generation SAPIEN 3 pulmonic delivery system (models 9631PL20, 9631PL23, 9631PL26, and 9631PL29) and various updates to the Magnetic Resonance (MR) Safety information in the device labeling.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.